CMMB logo

Chemomab Therapeutics Ltd. Stock Price

NasdaqCM:CMMB Community·US$11.6m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

CMMB Share Price Performance

US$0
-7.96 (-100.00%)
US$0
-7.96 (-100.00%)
Price US$0

CMMB Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Medium-low risk with adequate balance sheet.

7 Risks
0 Rewards

Chemomab Therapeutics Ltd. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$10.1m

Other Expenses

-US$10.1m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-1.64
0%
0%
0%
View Full Analysis

About CMMB

Founded
2011
Employees
n/a
CEO
Adi George
WebsiteView website
www.chemomab.com

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Recent CMMB News & Updates

Recent updates

No updates